{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:39:21Z","timestamp":1778704761680,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ad.2013.05.007","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T18:56:28Z","timestamp":1376074588000},"page":"752-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Reacciones psoriasiformes parad\u00f3jicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo cl\u00ednico"],"prefix":"10.1016","volume":"105","author":[{"given":"R.","family":"Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2013.05.007_bib0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.05.007_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clindermatol.2007.08.015","article-title":"Triggering psoriasis: The role of infections and medications","volume":"25","author":"Fry","year":"2007","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0015","first-page":"1","article-title":"Integrated approach to comorbidity in patients with psoriasis","volume":"103","author":"Dauden","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2013.05.007_bib0020","first-page":"1","article-title":"Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis","volume":"103","author":"Dauden","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2013.05.007_bib0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1242\/dmm.009092","article-title":"Putting together the psoriasis puzzle: An update on developing targeted therapies","volume":"5","author":"Johnson-Huang","year":"2012","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ad.2013.05.007_bib0030","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.05.007_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0001-7310(10)70012-0","article-title":"Etanercept and infections","volume":"101","author":"Ribera","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2013.05.007_bib0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/1153420-S0-000000000-00000","article-title":"Adverse effects of biological agents in the treatment of psoriasis","volume":"11","author":"Rongioletti","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2008.10.060","article-title":"Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review","volume":"61","author":"Moustou","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase iiitrial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0065","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2013.05.007_bib0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0085","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase iii, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2013.05.007_bib0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10067-007-0789-5","article-title":"Tumor necrosis factor-a antagonist-induced psoriasis: Yet another paradox in medicine","volume":"27","author":"Aslanidis","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/09546630903559814","article-title":"Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series","volume":"22","author":"Bhutani","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2013.05.007_bib0100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00105-007-1451-5","article-title":"First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept","volume":"59","author":"Boms","year":"2008","journal-title":"Hautarzt"},{"key":"10.1016\/j.ad.2013.05.007_bib0105","first-page":"328","article-title":"Diffused suberitrodermic psoriasis induced by infliximab","volume":"59","author":"Bruzzese","year":"2007","journal-title":"Reumatismo"},{"key":"10.1016\/j.ad.2013.05.007_bib0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/039463200902200126","article-title":"Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis","volume":"22","author":"Bruzzese","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ad.2013.05.007_bib0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0151-9638(07)89192-7","article-title":"Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab","volume":"134","author":"Cavailhes","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ad.2013.05.007_bib0120","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1346-8138.2010.00789.x","article-title":"New-onset psoriasis associated with etanercept therapy","volume":"37","author":"Chen","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.05.007_bib0130","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.05.007_bib0135","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2013.05.007_bib0140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: A systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ad.2013.05.007_bib0145","first-page":"709","article-title":"Psoriasis induced by infliximab","volume":"24","author":"Fernandes","year":"2011","journal-title":"Acta Med Port"},{"key":"10.1016\/j.ad.2013.05.007_bib0150","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: A retrospective study","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2013.05.007_bib0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2230.2006.02315.x","article-title":"Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers","volume":"32","author":"Goiriz","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semarthrit.2007.05.004","article-title":"The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: A review","volume":"37","author":"Grinblat","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.05.007_bib0165","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases","volume":"6","author":"Guerra","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ad.2013.05.007_bib0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.crohns.2010.11.001","article-title":"Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect","volume":"5","author":"Iborra","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ad.2013.05.007_bib0175","first-page":"700","article-title":"Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: Is it really a paradoxical side effect?","volume":"30","author":"Joyau","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.05.007_bib0185","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2013.05.007_bib0190","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/039463200902200331","article-title":"Psoriasis induced by infliximab in a patient suffering from Crohn's disease","volume":"22","author":"Manni","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ad.2013.05.007_bib0195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00403-008-0831-8","article-title":"Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: Report on five cases","volume":"300","author":"Mossner","year":"2008","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ad.2013.05.007_bib0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5021\/ad.2009.21.1.60","article-title":"Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease","volume":"21","author":"Park","year":"2009","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000107622","article-title":"Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy","volume":"215","author":"Passarini","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2013.05.007_bib0210","article-title":"Biologics-induced autoimmune diseases","author":"Perez-Alvarez","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0215","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000339864","article-title":"Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: Case report and review","volume":"225","author":"Puig","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2013.05.007_bib0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/09546630902882089","article-title":"Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: A \u00abclass effect\u00bb of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?","volume":"21","author":"Rallis","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2013.05.007_bib0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D31ZH0D26Q","article-title":"A case of infliximab-induced psoriasis","volume":"14","author":"Richetta","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.ad.2013.05.007_bib0230","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/RHU.0b013e31823262c3","article-title":"Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis","volume":"17","author":"Safa","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0235","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.gastrohep.2011.04.003","article-title":"Ustekinumab in a patient with Crohn's disease and anti-TNF-alpha-induced psoriasis","volume":"34","author":"Sanso Sureda","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0240","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","article-title":"Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments","volume":"161","author":"Seneschal","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0245","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.05.007_bib0250","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.crohns.2011.12.007","article-title":"Infliximab-induced psoriasis during therapy for Crohn's disease","volume":"6","author":"Steinwurz","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.ad.2013.05.007_bib0255","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1586\/eci.09.18","article-title":"Paradoxical adverse effects of anti-TNF-alpha treatment: Onset or exacerbation of cutaneous disorders","volume":"5","author":"Viguier","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ad.2013.05.007_bib0260","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions","volume":"143","author":"De Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0265","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/RHU.0b013e318190dd88","article-title":"Biologic therapy (TNF-alpha antagonists)-induced psoriasis: A cytokine imbalance between TNF-alpha and IFN-alpha?","volume":"14","author":"Cuchacovich","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0270","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.05.007_bib0275","first-page":"408","article-title":"Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: Description of 3 cases and review of the literature","volume":"28","author":"Mourao","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0280","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0001-7310(10)70018-1","article-title":"Psoriasiform skin reactions during treatment with etanercept","volume":"101","author":"Santos-Juanes","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2013.05.007_bib0285","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1365-2133.2010.09669.x","article-title":"Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies","volume":"162","author":"Santos-Juanes","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0290","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","article-title":"Review article: Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease","volume":"29","author":"Fiorino","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2013.05.007_bib0295","first-page":"1411","article-title":"Anti-tumor necrosis factor-alpha-induced psoriasis","volume":"33","author":"Sari","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0300","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2310\/7750.2008.07080","article-title":"Occurrence of plantar pustular psoriasis during treatment with infliximab","volume":"13","author":"English","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2013.05.007_bib0305","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jbspin.2007.06.011","article-title":"Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ad.2013.05.007_bib0310","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000095033","article-title":"Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: Three further cases and current overview","volume":"213","author":"Pirard","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2013.05.007_bib0315","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0151-9638(07)89187-3","article-title":"Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases","volume":"134","author":"Lebas","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ad.2013.05.007_bib0320","first-page":"231","article-title":"Cutaneous adverse reaction to infliximab: Report of psoriasis developing in 3 patients","volume":"80","author":"Severs","year":"2007","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2013.05.007_bib0325","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ibd.20450","article-title":"Guttate psoriasis induced by infliximab in a child with Crohn's disease","volume":"14","author":"Costa-Romero","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ad.2013.05.007_bib0330","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2310\/7750.2011.10068","article-title":"Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab","volume":"15","author":"Alghamdi","year":"2011","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2013.05.007_bib0335","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1365-2133.2005.06977.x","article-title":"Infliximab can precipitate as well as worsen palmoplantar pustulosis: Possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?","volume":"153","author":"Michaelsson","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0340","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/DAD.0b013e3181cb3ff7","article-title":"Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies","volume":"32","author":"Laga","year":"2010","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ad.2013.05.007_bib0345","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.05.007_bib0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D38M24603S","article-title":"Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept","volume":"17","author":"Brigant","year":"2011","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.ad.2013.05.007_bib0355","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2036.2012.05126.x","article-title":"Letter: Pathogenesis of tumour necrosis factor-alpha antagonists-induced psoriasiform lesions","volume":"36","author":"Denadai","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2013.05.007_bib0360","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0004-28032012000200014","article-title":"The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: Should biological therapy be suspended?","volume":"49","author":"Denadai","year":"2012","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.ad.2013.05.007_bib0365","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ad.2011.04.012","article-title":"Episode of pustular psoriasis after a tuberculin test in a patient with plaque psoriasis on treatment with etanercept","volume":"102","author":"Guinovart","year":"2011","journal-title":"Actas Dermosifiliogr"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731013002548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731013002548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:02:03Z","timestamp":1757552523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731013002548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0001731013002548"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2013.05.007","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reacciones psoriasiformes parad\u00f3jicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo cl\u00ednico","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2013.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Espa\u00f1a, S.L.U. and AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}